デフォルト表紙
市場調査レポート
商品コード
1193240

白斑治療市場:薬剤クラスタイプ別、タイプ別、流通チャネル別:世界の機会分析および産業予測、2021-2031年

Vitiligo Treatment Market By Drug Class Type, By Type, By Distribution Channel : Global Opportunity Analysis and Industry Forecast, 2021-2031

出版日: | 発行: Allied Market Research | ページ情報: 英文 270 Pages | 納期: 2~3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=151.66円
白斑治療市場:薬剤クラスタイプ別、タイプ別、流通チャネル別:世界の機会分析および産業予測、2021-2031年
出版日: 2022年10月01日
発行: Allied Market Research
ページ情報: 英文 270 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

白斑治療の世界市場は、2021年に4億1,054万米ドルで、2022年から2031年にかけてCAGR4.3%を記録し、2031年には6億2,582万米ドルに達すると予測されます。

白斑は、皮膚に淡い色から白い斑点ができる長期的な症状です。また、その部分の毛髪は色素を失い、白く見えるようになります。これは、皮膚に存在する天然色素であるメラニンの不足が原因です。メラニンが不足すると、主に顔、首、手などの皮膚に白い斑点ができます。白斑の発症は20代半ばに始まりますが、中には年齢に関係なく発症する人もいます。白斑は自己免疫疾患であり、人の免疫系がメラノサイトを攻撃します。これらのメラノサイトは、メラニン合成を担っています。白斑治療は、皮膚の色を回復させることに基づいて行われます。

白斑治療市場の成長は、白斑の状態に悩む患者の増加によってもたらされます。例えば、2017年の米国生物工学情報センター(NCBI)によると、白斑の比較的高い有病率はアフリカ地域で確認されました。さらに、効果的な白斑治療のための研究開発活動の急増や、白斑の状態に関する意識の高まりは、市場の成長に向けて大きく貢献する要因となっています。

しかし、厳しい規制ルールや医薬品承認に要する時間の長さが市場の成長を妨げています。一方、ヘルスケア支出の増加は、市場成長の機会を生み出すと予想されます。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場の概要

  • 市場の定義と範囲
  • 主な調査結果
    • 主な投資ポケット
  • ポーターのファイブフォース分析
  • 主要企業のポジショニング
  • 市場力学
    • 促進要因
    • 抑制要因
    • 機会
  • COVID-19 影響分析

第4章 白斑治療市場:薬剤クラスタイプ別

  • 概要
    • 市場規模および予測
  • 副腎皮質ステロイド
    • 主な市場動向、成長要因、機会
    • 市場規模および予測:地域別
    • 市場分析:国別分析
    • 副腎皮質ステロイド白斑治療薬市場:投与経路別
      • 局所投与ルート市場規模・予測:地域別
      • 経口・全身投与ルート市場規模推移・予測:地域別
  • カルシニューリン阻害剤
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別
  • その他
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別

第5章 白斑治療市場:タイプ別

  • 概要
    • 市場規模・予測
  • セグメント別
    • 主な市場動向、成長要因と機会
    • 市場規模・予測:地域別
    • 市場分析:国別分析
  • ノンセグメント
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別

第6章 白斑治療市場:流通チャネル別

  • 概要
    • 市場規模および予測
  • 病院内薬局
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別
  • ドラッグストア、小売薬局
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別
  • オンラインプロバイダー
    • 主な市場動向、成長要因、機会
    • 市場規模・予測:地域別
    • 市場分析:国別

第7章 白斑治療市場:地域別

  • 概要
    • 市場規模・予測
  • 北米
    • 主な動向と機会
    • 北米の市場規模・予測:薬剤クラスタイプ別
      • 北米の副腎皮質ステロイド白斑治療市場:投与経路別
    • 北米の市場規模・予測:タイプ別
    • 北米市場規模・予測:流通チャネル別
    • 北米市場規模・予測:国別
      • 米国
      • カナダ
      • メキシコ
  • 欧州
    • 主要動向と機会
    • 欧州の市場規模・予測:薬剤クラスタイプ別
      • 欧州の副腎皮質ステロイド白斑治療市場:投与経路別
    • 欧州の市場規模・予測:タイプ別
    • 欧州市場規模・予測:流通チャネル別
    • 欧州市場規模・予測:国別
      • ドイツ
      • フランス
      • 英国
      • イタリア
      • スペイン
      • その他欧州
  • アジア太平洋地域
    • 主な動向と機会
    • アジア太平洋地域の市場規模・予測:薬剤クラスタイプ別
      • アジア太平洋地域の副腎皮質ステロイド白斑治療市場:投与経路別
    • アジア太平洋地域の市場規模・予測:タイプ別
    • アジア太平洋地域の市場規模・予測:流通チャネル別
    • アジア太平洋地域の市場規模・予測:国別
      • 日本
      • 中国
      • オーストラリア
      • インド
      • 韓国
      • その他アジア太平洋地域
  • LAMEA
    • 主な動向と機会
    • LAMEAの市場規模・予測:薬剤クラスタイプ別
      • LAMEAの副腎皮質ステロイド白斑治療市場:投与経路別
    • LAMEAの市場規模・予測:タイプ別
    • LAMEAの市場規模・予測:流通チャネル別
    • LAMEAの市場規模・予測:国別
      • ブラジル
      • サウジアラビア
      • 南アフリカ共和国
      • LAMEAの残りの地域

第8章 企業情勢

  • イントロダクション
  • 主要成功戦略
  • 主要10社の製品マッピング
  • 競合ダッシュボード
  • 競合のヒートマップ
  • 主な発展

第9章 企業プロファイル

  • Arcutis Biotherapeutics
  • Astellas Pharma Inc.
  • Bausch Health Companies Inc.
  • Belcher Pharmaceuticals, LCC
  • Celgene Corporation
  • clinuvel pharmaceuticals ltd
  • Dr. Reddy's Laboratories Ltd
  • Glenmark Pharmaceuticals Ltd
  • Mylan N.V.
  • Panacea Biotec Ltd
  • Pfizer Inc.
  • Strides Pharma Science Limited
図表

LIST OF TABLES

  • TABLE 1. GLOBAL VITILIGO TREATMENT MARKET, BY DRUG CLASS TYPE, 2021-2031 ($MILLION)
  • TABLE 2. VITILIGO TREATMENT MARKET, FOR CORTICOSTEROIDS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 3. VITILIGO TREATMENT MARKET FOR CORTICOSTEROIDS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 4. GLOBAL CORTICOSTEROIDS VITILIGO TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 5. VITILIGO TREATMENT MARKET, FOR TOPICAL ROUTE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 6. VITILIGO TREATMENT MARKET, FOR ORAL AND SYSTEMIC ROUTE, BY REGION, 2021-2031 ($MILLION)
  • TABLE 7. VITILIGO TREATMENT MARKET, FOR CALCINEURIN INHIBITOR, BY REGION, 2021-2031 ($MILLION)
  • TABLE 8. VITILIGO TREATMENT MARKET FOR CALCINEURIN INHIBITOR, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 9. VITILIGO TREATMENT MARKET, FOR OTHERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 10. VITILIGO TREATMENT MARKET FOR OTHERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 11. GLOBAL VITILIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 12. VITILIGO TREATMENT MARKET, FOR SEGMENTAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 13. VITILIGO TREATMENT MARKET FOR SEGMENTAL, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 14. VITILIGO TREATMENT MARKET, FOR NON SEGMENTAL, BY REGION, 2021-2031 ($MILLION)
  • TABLE 15. VITILIGO TREATMENT MARKET FOR NON SEGMENTAL, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 16. GLOBAL VITILIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 17. VITILIGO TREATMENT MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 18. VITILIGO TREATMENT MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 19. VITILIGO TREATMENT MARKET, FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2021-2031 ($MILLION)
  • TABLE 20. VITILIGO TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 21. VITILIGO TREATMENT MARKET, FOR ONLINE PROVIDERS, BY REGION, 2021-2031 ($MILLION)
  • TABLE 22. VITILIGO TREATMENT MARKET FOR ONLINE PROVIDERS, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 23. VITILIGO TREATMENT MARKET, BY REGION, 2021-2031 ($MILLION)
  • TABLE 24. NORTH AMERICA VITILIGO TREATMENT MARKET, BY DRUG CLASS TYPE, 2021-2031 ($MILLION)
  • TABLE 25. NORTH AMERICA CORTICOSTEROIDS VITILIGO TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 26. NORTH AMERICA VITILIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 27. NORTH AMERICA VITILIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 28. NORTH AMERICA VITILIGO TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 29. U.S. VITILIGO TREATMENT MARKET, BY DRUG CLASS TYPE, 2021-2031 ($MILLION)
  • TABLE 30. U.S. VITILIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 31. U.S. VITILIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 32. CANADA VITILIGO TREATMENT MARKET, BY DRUG CLASS TYPE, 2021-2031 ($MILLION)
  • TABLE 33. CANADA VITILIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 34. CANADA VITILIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 35. MEXICO VITILIGO TREATMENT MARKET, BY DRUG CLASS TYPE, 2021-2031 ($MILLION)
  • TABLE 36. MEXICO VITILIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 37. MEXICO VITILIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 38. EUROPE VITILIGO TREATMENT MARKET, BY DRUG CLASS TYPE, 2021-2031 ($MILLION)
  • TABLE 39. EUROPE CORTICOSTEROIDS VITILIGO TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 40. EUROPE VITILIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 41. EUROPE VITILIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 42. EUROPE VITILIGO TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 43. GERMANY VITILIGO TREATMENT MARKET, BY DRUG CLASS TYPE, 2021-2031 ($MILLION)
  • TABLE 44. GERMANY VITILIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 45. GERMANY VITILIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 46. FRANCE VITILIGO TREATMENT MARKET, BY DRUG CLASS TYPE, 2021-2031 ($MILLION)
  • TABLE 47. FRANCE VITILIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 48. FRANCE VITILIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 49. UK VITILIGO TREATMENT MARKET, BY DRUG CLASS TYPE, 2021-2031 ($MILLION)
  • TABLE 50. UK VITILIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 51. UK VITILIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 52. ITALY VITILIGO TREATMENT MARKET, BY DRUG CLASS TYPE, 2021-2031 ($MILLION)
  • TABLE 53. ITALY VITILIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 54. ITALY VITILIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 55. SPAIN VITILIGO TREATMENT MARKET, BY DRUG CLASS TYPE, 2021-2031 ($MILLION)
  • TABLE 56. SPAIN VITILIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 57. SPAIN VITILIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 58. REST OF EUROPE VITILIGO TREATMENT MARKET, BY DRUG CLASS TYPE, 2021-2031 ($MILLION)
  • TABLE 59. REST OF EUROPE VITILIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 60. REST OF EUROPE VITILIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 61. ASIA-PACIFIC VITILIGO TREATMENT MARKET, BY DRUG CLASS TYPE, 2021-2031 ($MILLION)
  • TABLE 62. ASIA-PACIFIC CORTICOSTEROIDS VITILIGO TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 63. ASIA-PACIFIC VITILIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 64. ASIA-PACIFIC VITILIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 65. ASIA-PACIFIC VITILIGO TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 66. JAPAN VITILIGO TREATMENT MARKET, BY DRUG CLASS TYPE, 2021-2031 ($MILLION)
  • TABLE 67. JAPAN VITILIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 68. JAPAN VITILIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 69. CHINA VITILIGO TREATMENT MARKET, BY DRUG CLASS TYPE, 2021-2031 ($MILLION)
  • TABLE 70. CHINA VITILIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 71. CHINA VITILIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 72. AUSTRALIA VITILIGO TREATMENT MARKET, BY DRUG CLASS TYPE, 2021-2031 ($MILLION)
  • TABLE 73. AUSTRALIA VITILIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 74. AUSTRALIA VITILIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 75. INDIA VITILIGO TREATMENT MARKET, BY DRUG CLASS TYPE, 2021-2031 ($MILLION)
  • TABLE 76. INDIA VITILIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 77. INDIA VITILIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 78. SOUTH KOREA VITILIGO TREATMENT MARKET, BY DRUG CLASS TYPE, 2021-2031 ($MILLION)
  • TABLE 79. SOUTH KOREA VITILIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 80. SOUTH KOREA VITILIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 81. REST OF ASIA-PACIFIC VITILIGO TREATMENT MARKET, BY DRUG CLASS TYPE, 2021-2031 ($MILLION)
  • TABLE 82. REST OF ASIA-PACIFIC VITILIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 83. REST OF ASIA-PACIFIC VITILIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 84. LAMEA VITILIGO TREATMENT MARKET, BY DRUG CLASS TYPE, 2021-2031 ($MILLION)
  • TABLE 85. LAMEA CORTICOSTEROIDS VITILIGO TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2021-2031 ($MILLION)
  • TABLE 86. LAMEA VITILIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 87. LAMEA VITILIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 88. LAMEA VITILIGO TREATMENT MARKET, BY COUNTRY, 2021-2031 ($MILLION)
  • TABLE 89. BRAZIL VITILIGO TREATMENT MARKET, BY DRUG CLASS TYPE, 2021-2031 ($MILLION)
  • TABLE 90. BRAZIL VITILIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 91. BRAZIL VITILIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 92. SAUDI ARABIA VITILIGO TREATMENT MARKET, BY DRUG CLASS TYPE, 2021-2031 ($MILLION)
  • TABLE 93. SAUDI ARABIA VITILIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 94. SAUDI ARABIA VITILIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 95. SOUTH AFRICA VITILIGO TREATMENT MARKET, BY DRUG CLASS TYPE, 2021-2031 ($MILLION)
  • TABLE 96. SOUTH AFRICA VITILIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 97. SOUTH AFRICA VITILIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 98. REST OF LAMEA VITILIGO TREATMENT MARKET, BY DRUG CLASS TYPE, 2021-2031 ($MILLION)
  • TABLE 99. REST OF LAMEA VITILIGO TREATMENT MARKET, BY TYPE, 2021-2031 ($MILLION)
  • TABLE 100. REST OF LAMEA VITILIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2021-2031 ($MILLION)
  • TABLE 101.ARCUTIS BIOTHERAPEUTICS: COMPANY SNAPSHOT
  • TABLE 102.ARCUTIS BIOTHERAPEUTICS: OPERATING SEGMENTS
  • TABLE 103.ARCUTIS BIOTHERAPEUTICS: PRODUCT PORTFOLIO
  • TABLE 104.ARCUTIS BIOTHERAPEUTICS: NET SALES,
  • TABLE 105.ARCUTIS BIOTHERAPEUTICS: KEY STRATERGIES
  • TABLE 106.ASTELLAS PHARMA INC.: COMPANY SNAPSHOT
  • TABLE 107.ASTELLAS PHARMA INC.: OPERATING SEGMENTS
  • TABLE 108.ASTELLAS PHARMA INC.: PRODUCT PORTFOLIO
  • TABLE 109.ASTELLAS PHARMA INC.: NET SALES,
  • TABLE 110.ASTELLAS PHARMA INC.: KEY STRATERGIES
  • TABLE 111.BAUSCH HEALTH COMPANIES INC.: COMPANY SNAPSHOT
  • TABLE 112.BAUSCH HEALTH COMPANIES INC.: OPERATING SEGMENTS
  • TABLE 113.BAUSCH HEALTH COMPANIES INC.: PRODUCT PORTFOLIO
  • TABLE 114.BAUSCH HEALTH COMPANIES INC.: NET SALES,
  • TABLE 115.BAUSCH HEALTH COMPANIES INC.: KEY STRATERGIES
  • TABLE 116.BELCHER PHARMACEUTICALS, LCC: COMPANY SNAPSHOT
  • TABLE 117.BELCHER PHARMACEUTICALS, LCC: OPERATING SEGMENTS
  • TABLE 118.BELCHER PHARMACEUTICALS, LCC: PRODUCT PORTFOLIO
  • TABLE 119.BELCHER PHARMACEUTICALS, LCC: NET SALES,
  • TABLE 120.BELCHER PHARMACEUTICALS, LCC: KEY STRATERGIES
  • TABLE 121.CELGENE CORPORATION: COMPANY SNAPSHOT
  • TABLE 122.CELGENE CORPORATION: OPERATING SEGMENTS
  • TABLE 123.CELGENE CORPORATION: PRODUCT PORTFOLIO
  • TABLE 124.CELGENE CORPORATION: NET SALES,
  • TABLE 125.CELGENE CORPORATION: KEY STRATERGIES
  • TABLE 126.CLINUVEL PHARMACEUTICALS LTD: COMPANY SNAPSHOT
  • TABLE 127.CLINUVEL PHARMACEUTICALS LTD: OPERATING SEGMENTS
  • TABLE 128.CLINUVEL PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
  • TABLE 129.CLINUVEL PHARMACEUTICALS LTD: NET SALES,
  • TABLE 130.CLINUVEL PHARMACEUTICALS LTD: KEY STRATERGIES
  • TABLE 131.DR. REDDY'S LABORATORIES LTD: COMPANY SNAPSHOT
  • TABLE 132.DR. REDDY'S LABORATORIES LTD: OPERATING SEGMENTS
  • TABLE 133.DR. REDDY'S LABORATORIES LTD: PRODUCT PORTFOLIO
  • TABLE 134.DR. REDDY'S LABORATORIES LTD: NET SALES,
  • TABLE 135.DR. REDDY'S LABORATORIES LTD: KEY STRATERGIES
  • TABLE 136.GLENMARK PHARMACEUTICALS LTD: COMPANY SNAPSHOT
  • TABLE 137.GLENMARK PHARMACEUTICALS LTD: OPERATING SEGMENTS
  • TABLE 138.GLENMARK PHARMACEUTICALS LTD: PRODUCT PORTFOLIO
  • TABLE 139.GLENMARK PHARMACEUTICALS LTD: NET SALES,
  • TABLE 140.GLENMARK PHARMACEUTICALS LTD: KEY STRATERGIES
  • TABLE 141.MYLAN N.V.: COMPANY SNAPSHOT
  • TABLE 142.MYLAN N.V.: OPERATING SEGMENTS
  • TABLE 143.MYLAN N.V.: PRODUCT PORTFOLIO
  • TABLE 144.MYLAN N.V.: NET SALES,
  • TABLE 145.MYLAN N.V.: KEY STRATERGIES
  • TABLE 146.PANACEA BIOTEC LTD: COMPANY SNAPSHOT
  • TABLE 147.PANACEA BIOTEC LTD: OPERATING SEGMENTS
  • TABLE 148.PANACEA BIOTEC LTD: PRODUCT PORTFOLIO
  • TABLE 149.PANACEA BIOTEC LTD: NET SALES,
  • TABLE 150.PANACEA BIOTEC LTD: KEY STRATERGIES
  • TABLE 151.PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 152.PFIZER INC.: OPERATING SEGMENTS
  • TABLE 153.PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 154.PFIZER INC.: NET SALES,
  • TABLE 155.PFIZER INC.: KEY STRATERGIES
  • TABLE 156.STRIDES PHARMA SCIENCE LIMITED: COMPANY SNAPSHOT
  • TABLE 157.STRIDES PHARMA SCIENCE LIMITED: OPERATING SEGMENTS
  • TABLE 158.STRIDES PHARMA SCIENCE LIMITED: PRODUCT PORTFOLIO
  • TABLE 159.STRIDES PHARMA SCIENCE LIMITED: NET SALES,
  • TABLE 160.STRIDES PHARMA SCIENCE LIMITED: KEY STRATERGIES

LIST OF FIGURES

  • FIGURE 1.VITILIGO TREATMENT MARKET SEGMENTATION
  • FIGURE 2.VITILIGO TREATMENT MARKET,2021-2031
  • FIGURE 3.VITILIGO TREATMENT MARKET,2021-2031
  • FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
  • FIGURE 5.PORTER FIVE-1
  • FIGURE 6.PORTER FIVE-2
  • FIGURE 7.PORTER FIVE-3
  • FIGURE 8.PORTER FIVE-4
  • FIGURE 9.PORTER FIVE-5
  • FIGURE 10.TOP PLAYER POSITIONING
  • FIGURE 11.VITILIGO TREATMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
  • FIGURE 12.VITILIGO TREATMENT MARKET,BY DRUG CLASS TYPE,2021(%)
  • FIGURE 13.COMPARATIVE SHARE ANALYSIS OF CORTICOSTEROIDS VITILIGO TREATMENT MARKET,2021-2031(%)
  • FIGURE 14.COMPARATIVE SHARE ANALYSIS OF CALCINEURIN INHIBITOR VITILIGO TREATMENT MARKET,2021-2031(%)
  • FIGURE 15.COMPARATIVE SHARE ANALYSIS OF OTHERS VITILIGO TREATMENT MARKET,2021-2031(%)
  • FIGURE 16.VITILIGO TREATMENT MARKET,BY TYPE,2021(%)
  • FIGURE 17.COMPARATIVE SHARE ANALYSIS OF SEGMENTAL VITILIGO TREATMENT MARKET,2021-2031(%)
  • FIGURE 18.COMPARATIVE SHARE ANALYSIS OF NON SEGMENTAL VITILIGO TREATMENT MARKET,2021-2031(%)
  • FIGURE 19.VITILIGO TREATMENT MARKET,BY DISTRIBUTION CHANNEL,2021(%)
  • FIGURE 20.COMPARATIVE SHARE ANALYSIS OF HOSPITAL PHARMACIES VITILIGO TREATMENT MARKET,2021-2031(%)
  • FIGURE 21.COMPARATIVE SHARE ANALYSIS OF DRUG STORES AND RETAIL PHARMACIES VITILIGO TREATMENT MARKET,2021-2031(%)
  • FIGURE 22.COMPARATIVE SHARE ANALYSIS OF ONLINE PROVIDERS VITILIGO TREATMENT MARKET,2021-2031(%)
  • FIGURE 23.VITILIGO TREATMENT MARKET BY REGION,2021
  • FIGURE 24.U.S. VITILIGO TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 25.CANADA VITILIGO TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 26.MEXICO VITILIGO TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 27.GERMANY VITILIGO TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 28.FRANCE VITILIGO TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 29.UK VITILIGO TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 30.ITALY VITILIGO TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 31.SPAIN VITILIGO TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 32.REST OF EUROPE VITILIGO TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 33.JAPAN VITILIGO TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 34.CHINA VITILIGO TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 35.AUSTRALIA VITILIGO TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 36.INDIA VITILIGO TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 37.SOUTH KOREA VITILIGO TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 38.REST OF ASIA-PACIFIC VITILIGO TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 39.BRAZIL VITILIGO TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 40.SAUDI ARABIA VITILIGO TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 41.SOUTH AFRICA VITILIGO TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 42.REST OF LAMEA VITILIGO TREATMENT MARKET,2021-2031($MILLION)
  • FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
  • FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
  • FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
  • FIGURE 46.PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 47.COMPETITIVE DASHBOARD
  • FIGURE 48.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
  • FIGURE 49.ARCUTIS BIOTHERAPEUTICS.: NET SALES ,($MILLION)
  • FIGURE 50.ASTELLAS PHARMA INC..: NET SALES ,($MILLION)
  • FIGURE 51.BAUSCH HEALTH COMPANIES INC..: NET SALES ,($MILLION)
  • FIGURE 52.BELCHER PHARMACEUTICALS, LCC.: NET SALES ,($MILLION)
  • FIGURE 53.CELGENE CORPORATION.: NET SALES ,($MILLION)
  • FIGURE 54.CLINUVEL PHARMACEUTICALS LTD.: NET SALES ,($MILLION)
  • FIGURE 55.DR. REDDY'S LABORATORIES LTD.: NET SALES ,($MILLION)
  • FIGURE 56.GLENMARK PHARMACEUTICALS LTD.: NET SALES ,($MILLION)
  • FIGURE 57.MYLAN N.V..: NET SALES ,($MILLION)
  • FIGURE 58.PANACEA BIOTEC LTD.: NET SALES ,($MILLION)
  • FIGURE 59.PFIZER INC..: NET SALES ,($MILLION)
  • FIGURE 60.STRIDES PHARMA SCIENCE LIMITED.: NET SALES ,($MILLION)
目次
Product Code: A31464

The global vitiligo treatment market was valued at $410.54 million in 2021, and is projected to reach $625.82 million by 2031, registering a CAGR of 4.3% from 2022 to 2031. 

Vitiligo is a long-term condition in which pale to white patches develop on the skin. In addition, hair on these areas of skin lose their pigment and appear white. This is caused by lack of melanin, which is a natural pigment present in the skin. Lack of melanin can lead to development of white patches on the skin primarily on face, neck, and hands. The onset of vitiligo starts in mid-twenties, however in some individuals it can appear at any age. It is an autoimmune disorder in which a person's immune system attack the melanocytes. These melanocytes are responsible for melanin synthesis. The treatment for vitiligo is based on restoring the skin color.

The vitiligo treatment market growth is driven by increase in patients suffering from vitiligo conditions. For instance, according to National Center for Biotechnology Information (NCBI) in 2017, a relatively high prevalence of vitiligo was found in Africa region. Furthermore, surge in R&D activities for effective vitiligo treatment and rise in awareness regarding vitiligo conditions are the factors that significantly contribute toward the growth of the market.

However, strict regulatory rules and long procedures for drug approvals hinder the growth of the market. On the other side, increase in healthcare expenditure is expected to create opportunities for the growth of the market.

The vitiligo treatment market is segmented into drug class type, type, distribution channel, and region. By drug class type the market is categorized into corticosteroids, calcineurin inhibitor, and others. Depending on type, it is fragmented into segmental and non-segmental. On the basis of distribution channel, it is divided into hospital pharmacies, drug stores and retail pharmacies, and online providers. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Major key players that operate in the global vitiligo treatment market are Arcutis Biotherapeutics, Astellas Pharma Inc., Bausch Health Companies Inc. (Bausch+Lomb Inc.), Bristol-Meyers Squibb (Celegen), Dermavant Science Inc., Dr. Reddy's Laboratories Ltd, Incyte Corporation, Merck kGaA, Pfizer Inc., Viatirs Inc. (Mylan N.V.).

Key Benefits For Stakeholders

  • This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the vitiligo treatment market analysis from 2021 to 2031 to identify the prevailing vitiligo treatment market opportunities.
  • The market research is offered along with information related to key drivers, restraints, and opportunities.
  • Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
  • In-depth analysis of the vitiligo treatment market segmentation assists to determine the prevailing market opportunities.
  • Major countries in each region are mapped according to their revenue contribution to the global market.
  • Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
  • The report includes the analysis of the regional as well as global vitiligo treatment market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

  • Segmental
  • Non Segmental

By Distribution Channel

  • Drug Stores and Retail Pharmacies
  • Online Providers
  • Hospital Pharmacies

By Drug Class Type

  • Corticosteroids
    • Route of Administration
    • Topical Route
    • Oral and Systemic Route
  • Calcineurin Inhibitor
  • Others

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest Of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest Of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest Of LAMEA
  • Key Market Players
    • Arcutis Biotherapeutics
    • Astellas Pharma Inc.
    • Bausch Health Companies Inc.
    • Belcher Pharmaceuticals, LCC
    • Celgene Corporation
    • clinuvel pharmaceuticals ltd
    • Dr. Reddy's Laboratories Ltd
    • Glenmark Pharmaceuticals Ltd
    • Mylan N.V.
    • Panacea Biotec Ltd
    • Pfizer Inc.
    • Strides Pharma Science Limited

TABLE OF CONTENTS

CHAPTER 1:INTRODUCTION

  • 1.1.Report description
  • 1.2.Key market segments
  • 1.3.Key benefits to the stakeholders
  • 1.4.Research Methodology
    • 1.4.1.Secondary research
    • 1.4.2.Primary research
    • 1.4.3.Analyst tools and models

CHAPTER 2:EXECUTIVE SUMMARY

  • 2.1.Key findings of the study
  • 2.2.CXO Perspective

CHAPTER 3:MARKET OVERVIEW

  • 3.1.Market definition and scope
  • 3.2.Key findings
    • 3.2.1.Top investment pockets
  • 3.3.Porter's five forces analysis
  • 3.4.Top player positioning
  • 3.5.Market dynamics
    • 3.5.1.Drivers
    • 3.5.2.Restraints
    • 3.5.3.Opportunities
  • 3.6.COVID-19 Impact Analysis on the market

CHAPTER 4: VITILIGO TREATMENT MARKET, BY DRUG CLASS TYPE

  • 4.1 Overview
    • 4.1.1 Market size and forecast
  • 4.2 Corticosteroids
    • 4.2.1 Key market trends, growth factors and opportunities
    • 4.2.2 Market size and forecast, by region
    • 4.2.3 Market analysis by country
    • 4.2.4 Corticosteroids Vitiligo Treatment Market by Route of Administration
      • 4.2.4.1 Topical Route Market size and forecast, by region
      • 4.2.4.2 Oral and Systemic Route Market size and forecast, by region
  • 4.3 Calcineurin Inhibitor
    • 4.3.1 Key market trends, growth factors and opportunities
    • 4.3.2 Market size and forecast, by region
    • 4.3.3 Market analysis by country
  • 4.4 Others
    • 4.4.1 Key market trends, growth factors and opportunities
    • 4.4.2 Market size and forecast, by region
    • 4.4.3 Market analysis by country

CHAPTER 5: VITILIGO TREATMENT MARKET, BY TYPE

  • 5.1 Overview
    • 5.1.1 Market size and forecast
  • 5.2 Segmental
    • 5.2.1 Key market trends, growth factors and opportunities
    • 5.2.2 Market size and forecast, by region
    • 5.2.3 Market analysis by country
  • 5.3 Non Segmental
    • 5.3.1 Key market trends, growth factors and opportunities
    • 5.3.2 Market size and forecast, by region
    • 5.3.3 Market analysis by country

CHAPTER 6: VITILIGO TREATMENT MARKET, BY DISTRIBUTION CHANNEL

  • 6.1 Overview
    • 6.1.1 Market size and forecast
  • 6.2 Hospital Pharmacies
    • 6.2.1 Key market trends, growth factors and opportunities
    • 6.2.2 Market size and forecast, by region
    • 6.2.3 Market analysis by country
  • 6.3 Drug Stores and Retail Pharmacies
    • 6.3.1 Key market trends, growth factors and opportunities
    • 6.3.2 Market size and forecast, by region
    • 6.3.3 Market analysis by country
  • 6.4 Online Providers
    • 6.4.1 Key market trends, growth factors and opportunities
    • 6.4.2 Market size and forecast, by region
    • 6.4.3 Market analysis by country

CHAPTER 7: VITILIGO TREATMENT MARKET, BY REGION

  • 7.1 Overview
    • 7.1.1 Market size and forecast
  • 7.2 North America
    • 7.2.1 Key trends and opportunities
    • 7.2.2 North America Market size and forecast, by Drug Class Type
      • 7.2.2.1 North America Corticosteroids Vitiligo Treatment Market by Route of Administration
    • 7.2.3 North America Market size and forecast, by Type
    • 7.2.4 North America Market size and forecast, by Distribution Channel
    • 7.2.5 North America Market size and forecast, by country
      • 7.2.5.1 U.S.
      • 7.2.5.1.1 Market size and forecast, by Drug Class Type
      • 7.2.5.1.2 Market size and forecast, by Type
      • 7.2.5.1.3 Market size and forecast, by Distribution Channel
      • 7.2.5.2 Canada
      • 7.2.5.2.1 Market size and forecast, by Drug Class Type
      • 7.2.5.2.2 Market size and forecast, by Type
      • 7.2.5.2.3 Market size and forecast, by Distribution Channel
      • 7.2.5.3 Mexico
      • 7.2.5.3.1 Market size and forecast, by Drug Class Type
      • 7.2.5.3.2 Market size and forecast, by Type
      • 7.2.5.3.3 Market size and forecast, by Distribution Channel
  • 7.3 Europe
    • 7.3.1 Key trends and opportunities
    • 7.3.2 Europe Market size and forecast, by Drug Class Type
      • 7.3.2.1 Europe Corticosteroids Vitiligo Treatment Market by Route of Administration
    • 7.3.3 Europe Market size and forecast, by Type
    • 7.3.4 Europe Market size and forecast, by Distribution Channel
    • 7.3.5 Europe Market size and forecast, by country
      • 7.3.5.1 Germany
      • 7.3.5.1.1 Market size and forecast, by Drug Class Type
      • 7.3.5.1.2 Market size and forecast, by Type
      • 7.3.5.1.3 Market size and forecast, by Distribution Channel
      • 7.3.5.2 France
      • 7.3.5.2.1 Market size and forecast, by Drug Class Type
      • 7.3.5.2.2 Market size and forecast, by Type
      • 7.3.5.2.3 Market size and forecast, by Distribution Channel
      • 7.3.5.3 UK
      • 7.3.5.3.1 Market size and forecast, by Drug Class Type
      • 7.3.5.3.2 Market size and forecast, by Type
      • 7.3.5.3.3 Market size and forecast, by Distribution Channel
      • 7.3.5.4 Italy
      • 7.3.5.4.1 Market size and forecast, by Drug Class Type
      • 7.3.5.4.2 Market size and forecast, by Type
      • 7.3.5.4.3 Market size and forecast, by Distribution Channel
      • 7.3.5.5 Spain
      • 7.3.5.5.1 Market size and forecast, by Drug Class Type
      • 7.3.5.5.2 Market size and forecast, by Type
      • 7.3.5.5.3 Market size and forecast, by Distribution Channel
      • 7.3.5.6 Rest of Europe
      • 7.3.5.6.1 Market size and forecast, by Drug Class Type
      • 7.3.5.6.2 Market size and forecast, by Type
      • 7.3.5.6.3 Market size and forecast, by Distribution Channel
  • 7.4 Asia-Pacific
    • 7.4.1 Key trends and opportunities
    • 7.4.2 Asia-Pacific Market size and forecast, by Drug Class Type
      • 7.4.2.1 Asia-Pacific Corticosteroids Vitiligo Treatment Market by Route of Administration
    • 7.4.3 Asia-Pacific Market size and forecast, by Type
    • 7.4.4 Asia-Pacific Market size and forecast, by Distribution Channel
    • 7.4.5 Asia-Pacific Market size and forecast, by country
      • 7.4.5.1 Japan
      • 7.4.5.1.1 Market size and forecast, by Drug Class Type
      • 7.4.5.1.2 Market size and forecast, by Type
      • 7.4.5.1.3 Market size and forecast, by Distribution Channel
      • 7.4.5.2 China
      • 7.4.5.2.1 Market size and forecast, by Drug Class Type
      • 7.4.5.2.2 Market size and forecast, by Type
      • 7.4.5.2.3 Market size and forecast, by Distribution Channel
      • 7.4.5.3 Australia
      • 7.4.5.3.1 Market size and forecast, by Drug Class Type
      • 7.4.5.3.2 Market size and forecast, by Type
      • 7.4.5.3.3 Market size and forecast, by Distribution Channel
      • 7.4.5.4 India
      • 7.4.5.4.1 Market size and forecast, by Drug Class Type
      • 7.4.5.4.2 Market size and forecast, by Type
      • 7.4.5.4.3 Market size and forecast, by Distribution Channel
      • 7.4.5.5 South Korea
      • 7.4.5.5.1 Market size and forecast, by Drug Class Type
      • 7.4.5.5.2 Market size and forecast, by Type
      • 7.4.5.5.3 Market size and forecast, by Distribution Channel
      • 7.4.5.6 Rest of Asia-Pacific
      • 7.4.5.6.1 Market size and forecast, by Drug Class Type
      • 7.4.5.6.2 Market size and forecast, by Type
      • 7.4.5.6.3 Market size and forecast, by Distribution Channel
  • 7.5 LAMEA
    • 7.5.1 Key trends and opportunities
    • 7.5.2 LAMEA Market size and forecast, by Drug Class Type
      • 7.5.2.1 LAMEA Corticosteroids Vitiligo Treatment Market by Route of Administration
    • 7.5.3 LAMEA Market size and forecast, by Type
    • 7.5.4 LAMEA Market size and forecast, by Distribution Channel
    • 7.5.5 LAMEA Market size and forecast, by country
      • 7.5.5.1 Brazil
      • 7.5.5.1.1 Market size and forecast, by Drug Class Type
      • 7.5.5.1.2 Market size and forecast, by Type
      • 7.5.5.1.3 Market size and forecast, by Distribution Channel
      • 7.5.5.2 Saudi Arabia
      • 7.5.5.2.1 Market size and forecast, by Drug Class Type
      • 7.5.5.2.2 Market size and forecast, by Type
      • 7.5.5.2.3 Market size and forecast, by Distribution Channel
      • 7.5.5.3 South Africa
      • 7.5.5.3.1 Market size and forecast, by Drug Class Type
      • 7.5.5.3.2 Market size and forecast, by Type
      • 7.5.5.3.3 Market size and forecast, by Distribution Channel
      • 7.5.5.4 Rest of LAMEA
      • 7.5.5.4.1 Market size and forecast, by Drug Class Type
      • 7.5.5.4.2 Market size and forecast, by Type
      • 7.5.5.4.3 Market size and forecast, by Distribution Channel

CHAPTER 8: COMPANY LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top winning strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Key developments

CHAPTER 9: COMPANY PROFILES

  • 9.1 Arcutis Biotherapeutics
    • 9.1.1 Company overview
    • 9.1.2 Company snapshot
    • 9.1.3 Operating business segments
    • 9.1.4 Product portfolio
    • 9.1.5 Business performance
    • 9.1.6 Key strategic moves and developments
  • 9.2 Astellas Pharma Inc.
    • 9.2.1 Company overview
    • 9.2.2 Company snapshot
    • 9.2.3 Operating business segments
    • 9.2.4 Product portfolio
    • 9.2.5 Business performance
    • 9.2.6 Key strategic moves and developments
  • 9.3 Bausch Health Companies Inc.
    • 9.3.1 Company overview
    • 9.3.2 Company snapshot
    • 9.3.3 Operating business segments
    • 9.3.4 Product portfolio
    • 9.3.5 Business performance
    • 9.3.6 Key strategic moves and developments
  • 9.4 Belcher Pharmaceuticals, LCC
    • 9.4.1 Company overview
    • 9.4.2 Company snapshot
    • 9.4.3 Operating business segments
    • 9.4.4 Product portfolio
    • 9.4.5 Business performance
    • 9.4.6 Key strategic moves and developments
  • 9.5 Celgene Corporation
    • 9.5.1 Company overview
    • 9.5.2 Company snapshot
    • 9.5.3 Operating business segments
    • 9.5.4 Product portfolio
    • 9.5.5 Business performance
    • 9.5.6 Key strategic moves and developments
  • 9.6 clinuvel pharmaceuticals ltd
    • 9.6.1 Company overview
    • 9.6.2 Company snapshot
    • 9.6.3 Operating business segments
    • 9.6.4 Product portfolio
    • 9.6.5 Business performance
    • 9.6.6 Key strategic moves and developments
  • 9.7 Dr. Reddy's Laboratories Ltd
    • 9.7.1 Company overview
    • 9.7.2 Company snapshot
    • 9.7.3 Operating business segments
    • 9.7.4 Product portfolio
    • 9.7.5 Business performance
    • 9.7.6 Key strategic moves and developments
  • 9.8 Glenmark Pharmaceuticals Ltd
    • 9.8.1 Company overview
    • 9.8.2 Company snapshot
    • 9.8.3 Operating business segments
    • 9.8.4 Product portfolio
    • 9.8.5 Business performance
    • 9.8.6 Key strategic moves and developments
  • 9.9 Mylan N.V.
    • 9.9.1 Company overview
    • 9.9.2 Company snapshot
    • 9.9.3 Operating business segments
    • 9.9.4 Product portfolio
    • 9.9.5 Business performance
    • 9.9.6 Key strategic moves and developments
  • 9.10 Panacea Biotec Ltd
    • 9.10.1 Company overview
    • 9.10.2 Company snapshot
    • 9.10.3 Operating business segments
    • 9.10.4 Product portfolio
    • 9.10.5 Business performance
    • 9.10.6 Key strategic moves and developments
  • 9.11 Pfizer Inc.
    • 9.11.1 Company overview
    • 9.11.2 Company snapshot
    • 9.11.3 Operating business segments
    • 9.11.4 Product portfolio
    • 9.11.5 Business performance
    • 9.11.6 Key strategic moves and developments
  • 9.12 Strides Pharma Science Limited
    • 9.12.1 Company overview
    • 9.12.2 Company snapshot
    • 9.12.3 Operating business segments
    • 9.12.4 Product portfolio
    • 9.12.5 Business performance
    • 9.12.6 Key strategic moves and developments